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ABSTRACT 
Pathogenic microbial biofilm, a consortium of microbial cells protected by a self-
produced polymer matrix, is considered a worldwide challenge due to the inherent 
antibiotic resistance conferred by its lifestyle. Living, as it does, in a community of 
microbial organisms in a clinical situation, makes it responsible for severe and 
dangerous cases of infection. Combating this organisation of cells usually requires high 
antibiotic doses for a prolonged time, and these approaches often fail, contributing to 
infection persistence. In addition to therapeutic limitations, biofilms can be a source of 
infections when they grow inmedical devices. The challenge imposed by biofilms has 
mobilised researchers in the entire world to prospect or develop alternatives to control 
biofilms. In this context, this review summarises the new frontiers that could be used in 
clinical circumstances in order to prevent or eliminate pathogenic biofilms. 
 
1. Introduction 
Treatment of infections has become a worldwide challenge due to 
the development of antibiotic resistance among microorganisms, especially 
when resistance at cellular levels and at community level occur 
together (Fig. 1). Cellular antibiotic resistance, also referred to as conventional 
resistance, may occur when antibiotic targets are modified, 
microbial enzymes inactivate antibiotics and microorganisms prevent 
or reduce the antibiotic accumulation in their cells (Blair et al., 2015). 
Resistance observed in a community of microorganisms, known as 
biofilms, takes place when microbial cells aggregate (Bjarnsholt et al., 
2013; G. Zhou et al., 2015; L. Zhou et al., 2015). Resistance to antibiotics 
can be even higher when single cells that present conventional resistance 
form a biofilm. 
Biofilms consist of one or more microbial species, which can be 
in different metabolic states, encased in a self-produced biopolymer 
matrix composed by proteins, polysaccharides and DNA (Bjarnsholt 
et al., 2013) (Fig. 1). In clinical environments, this resistant profile can 
develop on human body tissue surfaces and medical devices (Romling 
et al., 2014). Antibiotic therapies against biofilms usually require the 
use of high doses for prolonged time, and they often fail to combat persistent 
infections associated with biofilms (Beloin et al., 2014). Besides, 
most available antibiotics have been developed to target planktonicmicrobial 
cells, leading to a big gap in the biofilm field. 
Potential candidates may act in preventing, disrupting, weakening 
or killing the microbial community within a biofilm (Bjarnsholt et al., 
2013). In the prevention, anti-biofilm compounds may kill the planktonic 
cell or block biofilm formation by living cells. In the disrupting 
process, anti-biofilm compounds may destabilise the matrix, making 
the microbial cells within the biofilms susceptible to antimicrobial 
and/or host defense mechanisms (Bjarnsholt et al., 2013). In the weakening 
approach, anti-biofilm agents may neutralise virulence factors or 
affect processes involved in biofilm formation, such as quorum sensing. 
In the killing process, anti-biofilmcompoundsmay present a bactericidal 
action upon microbial cells from biofilm (Bjarnsholt et al., 2013). 
In this review, we present different approaches that have been proposed 
to decrease biofilm formation (Fig. 1). Attempts to fight against 
these cellular organisations include drug repurposing, peptides and 
peptide-based composites, a combination of different compounds aiming 
to target different aspects of biofilm, development of nanomaterials 
to combat and/or improve the diagnostic biofilm infections and the 
development of medical devices made with anti-adherent material or 
functionalised with anti-biofilm compounds. 
 
 
Fig. 1. Schematic diagram showing a common biofilm profile, mechanisms of antibiotic 
resistance and possible anti-biofilm strategies. 
 
 
2. The challenge of resistant bacterial biofilms 
Currently, bacterial pathogenic biofilms are a remarkable challenge in 
the medical settings. Biofilm-associated infections are difficult to treat, 
usually requiring high antibiotic doses (Wu et al., 2015). The concentration 
of antibiotics to eradicate this bacterial organisation is commonly 
higher than that used to inhibit or kill its planktonic counterpart. This 
resistant life style can overcome host defenses and antibiotic therapies, 
contributing to the increase of morbidity and mortality in infected 
patients and consequently increasing hospital costs (Romling et al., 2014). 
Pathogenic biofilms are normally associated with a number of persistent 
and chronic infections such as otitis media (Qureishi et al., 
2014), periodontal disease (Jhajharia et al., 2015), non-healing wounds 
and skin infections (Cooper et al., 2014), lung infections in patients with 
cystic fibrosis (Ciofu et al., 2015), chronic rhinosinusitis (Madeo & Frieri, 
2013) and urogenital infections (Zhao et al., 2013). The success of 
biofilmdevelopment in host tissues could be related to immune defense 
failure in preventing microbial colonisation or in the elimination of 
existing biofilms. Otherwise, the prolonged and/or exacerbated response 
of the host defense against biofilms can damage the host tissue 
and the neighbourhood, where this microbial community develops, 
and this may progressively impact the life quality of patients with 
chronic infections (Beikler & Flemmig, 2011; Zhao et al., 2013; Helwig 
et al., 2014; Cantin et al., 2015). 
Some groups of people present a high risk of developing biofilm 
infections due to underlying diseases such as diabetes (Mottola et al., 
2015) and cystic fibrosis (Ciofu et al., 2015). They become more susceptible 
to the development of biofilm due to the poor ability of their body 
to limit biofilm formation. For example, impaired healing of wounds in 
diabetics may facilitate bacterial development of pathogenic biofilms 
(Hurlow et al., 2015). Patients with cystic fibrosis have difficulty in 
coughing up the sputum, making the lung an ideal place for the establishment 
of biofilm infections (Gupta et al., 2015). Other conditions 
can facilitate biofilm development, including the exposure of internal 
body parts to medical devices, such as implants and catheters (Gupta 
et al., 2015), and poor oral hygiene (Marsh, 2010). 
Moreover, biofilms can cause problems beyond the site where the 
biofilm resides, due to the dispersion of bacterial cells to other parts of 
the body or through the production of compounds that can trigger 
other diseases – apart from infections – such as cancer (Johnson et al., 
2015) and autoimmune diseases (Gallo et al., 2015). Oral biofilms in 
dentures, for example, can be a reservoir for pneumonia (O'Donnell 
et al., 2015). Bacterial cells from biofilm formed in central venous 
catheters can disperse and cause bacteraemia (Yousif et al., 2015). Interactions 
between biofilmcomponents such as amyloid curly protein and 
bacterial DNA, during biofilm formation can trigger an immune activation 
that induces a pathogenic response in systemic lupus erythematosus, 
suggesting that amyloids produced by bacteria may contribute to 
the progression of lupus (Gallo et al., 2015). In addition, pathogenic 
biofilms have also been detected on the inanimate surfaces of the hospital 
environment, including in intensive care units, affecting sites such 
mattresses, curtains and wire clips for holding patients (Hu et al., 
2015). In many cases, these biofilms have been formed by multidrugresistant 
strains (Wiley et al., 2012; Huet al., 2015). Pathogenic bacterial 
biofilms in natural water and foodmake these environments a potential 
source of nosocomial and community infections. 
Different factors can contribute to the resistant profile of bacteria 
in biofilms (Bjarnsholt et al., 2013). A high amount of biofilm matrix 
in mature biofilms for example, can physically limit the antibiotic diffusion 
within biofilm and consequently reduce the cell killing into biofilm 
(Holmberg & Rasmussen, 2016). Increased amount of biofilm matrix 
also can lead to creation of microenvironments with limited amount 
of nutrients and oxygen gradients, which may contribute to the slow 
metabolism of cells and consequently to the limited action of specific 
antibiotics which work better against active growing cells and in oxygenated 
conditions (Bjarnsholt et al., 2013; Olsen, 2015). Resistance 
due to reduced metabolism can also be reached by the development 
of persister cells, a subpopulation of dormant cells (Bjarnsholt et al., 
2013). Beyond these factors, matrix components such as extracellular 
DNA, can bind to antimicrobial agents, like aminoglycosides, and limit 
the action of antibiotics over microbial cells in biofilm (Wilton et al., 
2015). 
Individual cells can also contribute to antibiotic resistance in biofilms. 
Acquisition of antibiotic resistance trough incorporation of foreign 
genes and/or mutation can lead for example to antibiotic degradation 
or modification, active efflux of antimicrobial molecules from bacterial 
cell and modification of antibiotic target (Bjarnsholt et al., 2013). Environmental 
stress, such as the presence of antibiotic in growth conditions, 
can induce transitory resistance, regulating for example genes that produce 
enzymes which degrade antibiotics, alter components of cell membrane 
(blocking the entry of antibiotics) and upregulate efflux pump 
(Fernández & Hancock, 2012; Bjarnsholt et al., 2013). 
Biofilms in natural environments, including the human body, are 
usually polymicrobial (Bertesteanu et al., 2014; Swidsinski et al., 2014; 
Jakubovics, 2015). Biofilm diversity involves the presence of different 
strains of the same bacterial species, multiple bacterial species or even 
a mix of bacteria and fungi (Sztajer et al., 2014). In the clinical configuration, 
this condition can complicate antibiotic therapy. In addition, 
polymicrobial biofilms have been shown to be more resistant to detergents 
and to disinfectant, contributing to the maintenance of potential 
pathogens in the current clinical scene (Sanchez-Vizuete et al., 2015; 
Vikram et al., 2015). Multiple pathogenic microorganisms may be 
involved in different antimicrobial targets and, consequently, different 
antibiotic classes need to be used. Moreover, mixed species of biofilms 
can be more tolerant to antibiotics than single biofilm species (Lee 
et al., 2014). Besides, polymicrobial biofilms may cause infections in 
different systems of the human body or different clinical symptoms, 
making the diagnosis and antibiotic therapy difficult. 
Life in a community, in addition to conferring a defensive strategy 
against environmental stress on microbial cells (e.g., antimicrobials, 
host defense, desiccation, detergents, and others), also provides a scenario 
in which the emergence and spread of resistance can be maximised 
among individual cells within biofilms, improving both defensive and 
offensive strategies. Mutation rates are at least 100 times higher in cells 
within biofilm than in planktonic cells (Conibear et al., 2009), providing 
an increased possibility of developing antibiotic-resistant mutants. 
Proximity between cells from a biofilm facilitates the horizontal transfer 
of resistant genes and, consequently, the spread of resistance (Madsen 
et al., 2012). Savage et al. (2013), for example, observed that the horizontal 
spread of antibiotic resistance in Staphylococcus aureus biofilms is 
increased by plasmid transfer through conjugations and mobilisation. 
3. Old drugs that could be useful to control biofilms 
Antibiotics are the currently available drug used in clinical practice 
to treat these infections (Wu et al., 2015). However, this option is 
often inefficient, requiring the use of antibiotic combinatory therapy. 
In recent years, efforts have been driven by academic research groups 
to discover anti-biofilm agents. Some natural, synthetic or biological 
(such as bacteriophages) approaches have proved to be promising in 
combating biofilm infections (Wu et al., 2015). Despite the importance 
of discovering anti-biofilm agents, the process of putting a new drug on 
the market can be time-consuming and costly. It is estimated that it 
takes 15 years to put a new drug molecule on the market and a cost of 
about US$ 1 billion to bring a single medicine to the market. Moreover, 
there is little investment in the drug market to treat infectious diseases 
due to the poor economic returns for the pharmaceutical sector (Chong 
& Sullivan, 2007). 
The advantage of using drugs that are already on the market is 
mainly because they have already been tested in humans. The safety 
evaluation, pharmacokinetics and side effects are often known. Thus, 
the timing and cost associated with carrying out trials for newly 
identified molecules may be reduced. Identification of new uses for 
old drugs – also known as drug repurposing or drug repositioning – 
can reduce the expenses of putting a new medicine on the market by 
about 40% (Chong & Sullivan, 2007). 
Since patents do not cover most part of the approved drugs (9000 
out of 10,000 drugs), the possibility of screening new uses for classical 
drugs is greater (Chong & Sullivan, 2007). This renaissance scenario is 
particularly interesting from the point of view of finding agents to 
treat biofilm infections. The studies of biofilm development, biofilm 
associated infections, diagnosis and treatment are relatively new, 
and only about 30 years have passed since Professor Bill Costerton observed 
that chronic infections in patients under implanted medical devices 
were caused by bacteria growing in biofilms, an antibiotic and 
host-defense-resistant lifestyle (Lappin-Scott et al., 2014). High doses 
of antibiotics or antibiotic combinations have been used against biofilm 
infections; however, in many cases these approaches fail, making 
patients live chronically with pathogenic biofilms. The formation of 
biofilms by multi-drug resistant bacteria makes anti-biofilm therapy 
even more complicated. In order to overcome all these issues, there is 
an urgent need and demand to develop new antibiotics and also to discover 
and develop anti-biofilm agents. A faster approach to overcome 
this alarming situation would be by identifying anti-biofilm activity 
among existing drugs. 
Potential anti-biofilm activity has been found among FDA-approved 
(Food and Drug Administration) drugs such as anti-inflammatory, anticancer 
(Alem & Douglas, 2004; Attila et al., 2009; Naves et al., 2010; 
Ulusoy & Bosgelmez-Tinaz, 2013; Goggin et al., 2014; Reslinski et al., 
2015) and antidepressant drugs (Dean & van Hoek, 2015). Such drugs 
classes have been tested against bacterial and fungal biofilms. The 
anti-inflammatory drugs have shown anti-biofilm action against bacterial 
(Naves et al., 2010; Goggin et al., 2014; Reslinski et al., 2015) and 
fungal cells. Diclofenac and ibuprofen, for example, limited the biofilm 
formation of S. aureus and Escherichia coli (Reslinski et al., 2015). Studies 
with Pseudomonas aeruginosa suggested that the anti-biofilm action of 
the anti-inflammatory ketoprefen and diclofenac could be due to the 
interference in quorum-sensing signalling (Ulusoy & Bosgelmez-Tinaz, 
2013). Sodium diclofenac, aspirin and ibuprofen have also shown antibiofilm 
potential against Candida albicans (Alem & Douglas, 2004; 
Abdelmegeed & Shaaban, 2013). Inmammals, these drugs act by blocking 
the biosynthesis of prostaglandins (a lipid that plays an important role in 
the inflammatory response), through the inhibition of cyclooxygenase 
isoenzymes (Ricciotti & FitzGerald, 2011). Prostaglandins can also be produced 
by Candida cells in planktonic and biofilm state (Alem & Douglas, 
2005). The anti-biofilm mechanism of action of these drugs is unknown 
in Candida, but it is believed that they might act by interfering in prostaglandin 
biosynthesis (Alem & Douglas, 2004). 
Other categories of drugs, such as anticancer and antidepressant, 
have also shown anti-biofilm activity against infectious bacteria. For 
example, the anticancer drug 5-fluorouracil has shown ability in the 
reduction of biofilm formation of P. aeruginosa, E. coli and S. aureus 
(Attila et al., 2009). Attila et al. (2009) observed that 5-fluorouracil 
limits the biofilm formation of E. coli K-1 through AriR, a gene involved 
in the global regulation of biofilm and acid resistance. The antidepressant 
maprotiline inhibited Franciella novicida biofilm via signalling 
through 2-component systems (QseC-dependent) (Dean & van Hoek, 
2015). 
A combination of non-antibiotic FDA-approved drugs with existing 
antibiotics is an approach that could be useful in preventing biofilm formation. 
Here, Moreau-Marquis and colleagues showed that the FDAapproved 
iron chelators deferoxamine or deferasirox with tobramycin, 
(an antibiotic) kill existing biofilm of P. aeruginosa and limit biofilm 
formation on cystic fibrosis cells (Moreau-Marquis et al., 2009). 
Tobramycin and FDA-approved iron chelators eliminate P. aeruginosa 
biofilms on cystic fibrosis cells. Since iron availability is important for 
biofilm formation, the authors suggested that the limitation of this 
metal induced by the iron-binding activity of those iron chelators 
might contribute to increasing the action of tobramycin to inhibit or disrupt 
biofilm formation (Moreau-Marquis et al., 2009). 
Although drug repurposing seems to be a promising approach to 
prevent or combat biofilm infections, it is important to consider that 
the ideal anti-biofilm candidate would be a drug that is off-patent, 
safe and works for this purpose within the maximum recommended 
therapeutic dose for an already-approved indication — this principle 
is applicable for repurposing of candidates for any type of therapy 
(Oprea & Mestres, 2012). 
4. Peptides and other designed 
compounds with anti-biofilm activities 
Due to the clinical challenges in combating pathogenic biofilm by 
antibiotics, that are currently on the market, researchers worldwide 
have been exploring new anti-biofilmtherapeutic options.Most studies 
involving the currently available antibiotics used in the treatment of 
(acute or chronic) infections have been based on experiments with 
planktonic (free-floating) microorganisms (Bjarnsholt et al., 2013). 
The exploration of compounds to control chronic infections strengthened 
after the association of these infections with biofilms. Currently, 
awide numbers of compounds, natural or synthetic, have been evaluated 
as an option to combat pathogenic biofilm in several clinical fields. 
In this context, peptides and designed peptide-based compounds, 
such as peptidomimetics, have emerged as potential anti-biofilmagents 
(Mojsoska & Jenssen, 2015). 
Initially, in the context ofmicrobial infections, peptides from natural 
sources (vertebrates, invertebrates, plants, fungi and bacteria) have 
been widely explored for their direct antimicrobial potential against 
different pathogens, including bacteria, fungi, viruses and protozoa 
(Mojsoska & Jenssen, 2015). Later, some natural peptides were shown 
to be better for immunomodulatory than antimicrobial activities in 
physiological conditions found in vivo (presence of monovalent and 
divalent cations, serum and anionic polysaccharides) — improving the 
host defense response in an infection state (Fjell et al., 2012). The 
term “antimicrobial peptides” (AMPs) has been suggested when direct 
antimicrobial activity is observed and the term “host defense peptides” 
(HDPs) has been indicated when immunomodulatory functions are 
explored (Fjell et al., 2012). 
Currently, more than 2000 AMPs isolated from different living organisms 
are catalogued in the Antimicrobial Peptide Database (Wang 
et al., 2009). These peptides can be classified based on different characteristics, 
including length (less than 100 amino acid residues), net 
charge (cationic, anionic or neutral), structure (usually β-sheet, α- 
helix, extended, loop) and hydrophobicity (hydrophobic, amphipathic 
and hydrophilic). Such characteristics can influence the activity and 
mode of action of these peptides (Bahar & Ren, 2013), and they have 
been explored as a way to develop improved peptides. Improvements 
involve making these peptides into therapeutically suitable drugs, 
through optimisation and design, in order to increase their antimicrobial 
or immunomodulatory activity, reduce their toxicity and size (minimising 
the costs of manufacturing) and make them resistant to proteolytic 
degradation by host proteases. A common way to do this is by substituting, 
inserting or deleting specific amino-acid residues of natural HDPs. 
Another way is to develop peptidomimetics, such as antimicrobial 
peptoids, compounds based on peptides that present altered backbone 
or non-natural or rare amino acids, which are changes uncommon in 
nature (Mojsoska & Jenssen, 2015). 
Nowadays, in the “biofilm era”, many of those peptides (natural 
or synthetic antimicrobial and/or immunomodulatory) and antimicrobial 
peptidomimetics have proved to have action againstmicrobial 
biofilms (Mansour et al., 2015; Mojsoska & Jenssen, 2015). 
Currently, optimisation and design have been directed towards the 
development of anti-biofilm peptides/peptidomimetics. These 
compounds have been acclaimed as potential agents to combat 
biofilm in several clinical scenarios, including oral and wound sites, 
and on medical devices (Harding & Reynolds, 2014; Mansour et al., 
2015; Mojsoska & Jenssen, 2015; Wang et al., 2015). They have 
shown ability in preventing biofilm formation, dispersing existing 
ones, reducing biomass and/or killing microbial cells within biofilms 
(Segev-Zarko et al., 2015). 
Some peptides at specific concentrations are able to limit biofilm 
formation without affecting planktonic growth. For example, the natural 
peptide LL-37, its synthetic analogue 1037 (de la Fuente-Nunez 
et al., 2012), the immunomodulatory peptide IDR (innate defense 
regulator)-1018 and the D-enantiomeric peptides DJK-5 and DJK-6 are 
able to reduce or prevent biofilm formation at concentrations lower 
than the MIC (minimal inhibitory concentration) — i.e., the concentration 
used to inhibit the growth of planktonic cells (de la Fuente-Núñez 
et al., 2015; Ribeiro et al., 2015). This feature supports the idea that 
anti-biofilm activity is independent of antimicrobial activity (de la 
Fuente-Nunez et al., 2012). Interestingly, the anti-biofilm effect on 
pre-formed biofilms has also been shown to be concentrationdependent. 
For example, 0.8 μg.mL−1 of the peptide 1018 induces cell 
dispersion of P. aeruginosa biofilms, while 10 μg.mL−1 of this peptide 
triggers cell death within biofilms. Peptidomimetics, such the antimicrobial 
peptoid 1 and 1-C134mer, have shown an ability to eliminate 
existing P. aeruginosa biofilm at their MIC (Liu et al., 2013). Since 
the eradication of existing biofilm by conventional antibiotics usually 
requires doses much higher than their MIC (in some cases up to 1000 
times) (Hoiby et al., 2010), such antimicrobial peptoids could be a 
potential agent to treat persistent infections associated with biofilms. 
Studies have shown that some peptides exert their anti-biofilm 
activity through interference in the expression of genes involved with 
biofilm formation. The peptide LL-37, for example, downregulated 
genes associated with the assembly of flagella, which is important for 
adherence during biofilm development, and with quorum-sensing signalling 
of formation of P. aeruginosa (Overhage et al., 2008). Besides, 
LL-37 upregulated genes involved in twitchingmotility, a formof translocation 
over moist surfaces independent of flagella and mediated by 
the type IV pili (Mattick, 2002; Overhage et al., 2008). This could lead 
bacteria to move across the surface, thus limiting the formation of 
structured biofilms, like mushroom structures, as usually observed in 
flow cell experiments (Picioreanu et al., 2007). Recent studies have 
shown that the anti-biofilm activity of the peptide IDR1018 and of the 
D-enantiomeric peptides DJK-5 and DJK-6 could be associated with the 
degradation or prevention of accumulation of (p)ppGpp (guanosine 
pentaphosphate), an intracellular signal molecule involved in the 
formation and maintenance of biofilms. Thus, peptides must cross the 
cell membranes and affect intracellular targets, such as (p)ppGpp, to 
prevent or disrupt biofilms. 
The therapeutic use of improved peptides and/or peptidomimetics 
as anti-biofilm agents seems promising, since some of them can resist 
host conditions such as enzymatic degradation (Han et al., 2015; 
Wang et al., 2015), like those present in saliva (Wang et al., 2015) and 
physiologic ion levels (Choe et al., 2015). In addition to these characteristics, 
some peptides present immunomodulatory functions, which can 
improve the host response againstmicrobial cells. The peptide IDR1018, 
for example, at a concentration of 10 μg.mL−1, prevents biofilm formation 
and substantially kills cells within oral multispecies biofilms in 
the presence of human saliva (Wang et al., 2015), which can reduce 
peptide activity, as observed for human cathelicidin LL-37 (Bucki 
et al., 2008). With concentrations lower than 20 μg.mL−1 
(a concentration that did not affect planktonic cell growth) 1018 
inhibits a broad spectrum of bacteria (de la Fuente-Nunez et al., 
2014), including ESKAPE pathogens (that include Enterococcus faecium, 
S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, P. aeruginosa 
and Enterobacter species), considered by the Infectious Diseases Society 
of America to be the cause of the majority of hospital infections 
(Pendleton et al., 2013). Besides, a nontoxic effect of 1018 against 
human fibroblasts (200 μg.mL−1) (Steinstraesser et al., 2012) and 
erythrocytes (100 μg.mL−1) (Steinstraesser et al., 2012) was observed 
at concentrations higher than those used to demonstrate anti-biofilm 
activity. The peptide IDR1018 was also able to acceleratewound healing 
in S. aureus infected non-diabetic pigs in a concentration-dependent 
manner, when compared to a vehicle-treated control (Steinstraesser 
et al., 2012). Since Staphylococcal biofilms impair wound healing, as 
observed in a wound healing murine model (Schierle et al., 2009), 
the peptide IDR1018 could be a promising agent to treat cutaneous 
infection by disruption of the biofilm. 
5. The potential of synergistic drugs 
Microbial biofilms have been linked to a range of chronic infections, 
such as urinary, pulmonary, wound and prosthetic joint infections 
(Romling et al., 2014). The therapy to eliminate existing biofilms usually 
requires high and prolonged antibiotic doses, and this often fails to 
eradicate the biofilm infection. In many cases, combinatory antibiotic 
therapies are needed to eradicate biofilm infections (Wu et al., 
2015). Synergistic antibiotic combinations present several advantages: 
expanding the antimicrobial and anti-biofilm spectrum, further reducing 
the cytotoxicity due to the use of lower doses of drugs, and preventing 
the emergence of resistant bacterial mutants during therapy (de la 
Fuente-Nunez et al., 2014). 
Considering that biofilms resist antibiotic therapies through multifactorial 
mechanisms (Bjarnsholt et al., 2013), combining strategies 
could promote improved treatment of biofilm-related infections. Combined 
strategies could promote synergy due to interference in different 
biofilm targets, such as matrix components, persister cells (dormant 
microbial cells highly tolerant to antibiotics) and microbial diversity. 
Current studies to access anti-biofilm synergy between compounds 
involve agents with known and unknown mechanisms of antibacterial 
and anti-biofilm activity. Combinatory experiments with agents that 
present known action mechanisms include those that act in single cell 
targets, for example: membranes, efflux pump, protein synthesis, or 
that act on biofilmcomponentmatrix (e.g., extracellular DNA and polysaccharides) 
or signalling molecules (Bjarnsholt et al., 2013). 
Since a number of different compounds present anti-biofilm and/or 
antimicrobial action, the possibility of constructing diverse groups combining 
themis promising. Theways to test potential combinatory drugs 
include antibiotics already on the market and other compounds, such as 
natural or synthetic peptides, peptidomimetics, enzymes (e.g., DNases), 
bacteriophages (Chan & Abedon, 2015), essential oils, secondarymetabolites 
(Kunze et al., 2010), Food and Drug Administration (FDA) nonantibiotic 
drugs and others (Moreau-Marquis et al., 2009; Dean & van 
Hoek, 2015). Many of these compounds have shown higher activity in 
inhibiting or targeting existing biofilms when combined. 
Strategies to access synergy against biofilms involve predominantly 
a combination of two antibiotics and antibiotics with a remarkable 
diversity of potential anti-biofilm compounds. Some studies have also 
explored combinations between antibiotics and FDA non-antibiotic 
compounds, as way of repurposing drugs (Moreau-Marquis et al., 
2009). Successful combination therapy could have a positive outcome, 
using a combination of immunomodulatory (in order to improve the 
host response against biofilm infections) and anti-biofilm agents. However, 
the use of combinatory approaches with compounds that can 
modulate the immune system could be difficult, since this strategy 
requires more laborious experiments to assess immune response and 
microbial load (in vitro approaches using co-cultures of mammalian 
cells and microbial cells or in vivo experiments). 
Although in clinical practice the combination of antibiotics against 
biofilm infections is predominant, in many cases this strategy may 
have a tendency to fail (Wuet al., 2015), may be because the antibiotics 
used are ineffective against biofilmorganisation. Resistance to a combination 
of antibiotics could be due the usual polymicrobial nature of 
biofilms, to multi-drug resistance to antibiotics of some cells within 
the biofilm, due to the presence of persister cells or even due to a combination 
of all these situations. Following this line of thought, it is important 
to investigate not only anti-biofilm agents, but also to pursue 
antimicrobial agents that target multi-drug-resistant bacteria, such as 
methicillin-resistant S. aureus (MRSA) and carbapenem-resistant bacteria, 
which can reveal new insights about the use of synergetic drugs. In 
addition, it important to carry out more studies of combinations involving 
multispecies biofilms in order to target this organisation. 
6. Anti-biofilm nanotools 
With the increasing number of multidrug-resistant organisms, it is 
essential to focus on possible therapeutic molecules that can overcome 
and eliminate this threat. Nanotechnology is one of themost prominent 
areaswith the potential to tackle almost every aspect of microbial infections 
(Alves et al., 2010; Cavalieri et al., 2014; Zhu et al., 2014). In recent 
years, counting bacterial diagnosis, antibiotic delivery and medical devices, 
more than 10 nanoparticle-based products have been approved 
and marketed, which confirms the potential of this area. Even with 
this potential, and with widespread studies, there are some disadvantages 
that have not yet been overcome to combat bacterial infections, 
but many novel products could be used in the future to improve treatment 
and achieve total eradication. 
Nanotechnology has been applied to treat diseases and prevent 
health issues (Naik et al., 2015). One of the main areas in focus is the 
development of therapeutic nanoparticles (NPs) for anti-biofilm applications. 
NPs can be synthesised through many different methods and 
approaches (Tran & Tran, 2012). The reason why these molecules are 
so well studied and tested in the therapeutics of infections lies in their 
properties. Some of themhave shown inherent antimicrobial properties 
and improved retention time in the body, optimising the capacity to 
deliver one or more drugs (withminimal side effects and enhancing tissue 
distribution), reducing the probability of the development of bacterial 
resistance (Huh & Kwon, 2011; Tran & Tran, 2012). Amongst many 
examples,metal nanoparticles are themost explored in this field. Metal 
NPs are mainly constituted by a metal or metal oxide, such as silver 
(Ag), gold (Au), zinc oxide (ZnO), copper (Cu), iron (Fe) or magnesium 
fluoride (MgF2). Of these, Ag NPs show the most promising results, due 
to their high antimicrobial effects on bacteria and biofilms (Li et al., 
2008; Ruparelia et al., 2008; Lellouche et al., 2009; Liu et al., 2009; Car 
et al., 2014; Palanisamy et al., 2014; Salunke et al., 2014; Abdulkareem 
et al., 2015; LewisOscar et al., 2015; Manju et al., 2016). Their mechanism 
of action is not yet fully understood, but it is clear that the uptake 
of Ag+ ions occurs, followed by cell membrane rupture (Palanisamy 
et al., 2014). Besides this, researchers have studied the possibility of 
Ag NPs being attached to glass surfaces, showing that they have high 
anti-biofilm action and can be applied in novel biomedical devices 
(Taglietti et al., 2014). Even so, the application of these molecules in 
clinical settings has some disadvantages that need to be addressed, 
such as the potential toxicity of long-lasting exposure to metals and 
the specificity to the target tissues (Huh & Kwon, 2011). 
In order to avoid the toxicity problem, the synthesis of polymeric 
nanoparticles has also been proposed, with a different mode of action 
from that of metal nanoparticles (Turos et al., 2007). In this case, the 
NPs would function as drug carriers that deliver the therapeutic molecule 
into the infected tissue, especially those that are water-insoluble, 
improving the effect on the biofilm (Turos et al., 2007). Polymeric NPs 
also include chitosan-coated NPs (Pelgrift & Friedman, 2013). Their 
antimicrobial effect occurs through chitosan itself, acting at the membrane 
level and DNA of the bacteria, recruiting immune cells and chelating 
metalloproteins essential for biofilm growth (Pelgrift & Friedman, 
2013). 
Major efforts have been made to achieve the specificity of NPs to the 
target tissue. To this end, different antibody-conjugated NPs have been 
developed. The antibodies are attached to the nanoparticle surface, 
which will allow them to combat only the microorganism with the corresponding 
antigen (Look et al., 2010). These NPs are considered very 
promising in the fight against microbial infections due to the flexibility 
of their synthesis and to their possible function as drug or cytokine carriers, 
having a greater therapeutic effect. The limitation of these 
nanomaterials lies in the efficiency of the drug delivery and in the stimulation 
of the immune response, in the case of the drug and cytokine 
carriers, respectively (Smith et al., 2013). A more complex system is a 
combination of metal and antibody-conjugated NPs that was achieved 
by Norman and co-workers, synthesising gold nanorods with specific 
antibodies to target bacterial cells (Norman et al., 2008). In this case, 
gold was chosen due to its ability to absorb near-infrared (NIR) radiation, 
transferring the absorbed energy as heat to the bacterial surface, 
inducing irreparable cellular damage. Combining this antimicrobial 
effect with antibody targeting, it was possible to create a system 
that has an improved therapeutic effect with great specificity (Fig. 2) 
(Norman et al., 2008). 
Another example of the possible application of nanoparticles to antibiofilm 
therapeutics is nitric oxide (NO) NPs (Fig. 2). In this case, the 
nanoparticles work also as carriers of NO, which has an antimicrobial 
effect on the target cells, releasing reactive free radicals, similar to 
those produced by the inflammatory cells (Hetrick et al., 2009). The 
material that is used to synthesise the NPs is required to not react 
with NO, and is normally silica (Hetrick et al., 2009). Despite the proven 
advantages that these NPs have shown, toxicity is a major problem, as 
are the broad-spectrum target cells, raising questions about the possible 
therapeutic applications. Furthermore, regarding silica NPs, another example 
includes those with incorporated fluorescent dyes, without a 
therapeutic effect but more as bacterial cell monitors. In these cases, 
NPs have nearly 10,000 molecules of encapsulated dyes, which can be 
of only one type of dye or a system of two or more dyes acting as Förster 
resonance energy transfer (FRET) pairs (Zhao et al., 2004; Wang et al., 
2007). To target the bacterial cells, these NPs have specific antibodies attached 
to the surface. The possible application of these nanomaterials to 
therapeutics will help to identify new sites of infection even in the absence 




Fig. 2. Schematic diagram illustrating strategies that could be used for the development 
of anti-biofilm nanotools. 
 
Besides nanoparticles, liposomes and solid lipid NPs have been studied 
in order to have an antimicrobial and anti-biofilm effect (Muller 
et al., 2000; Torchilin, 2005) (Fig. 2). Different possibilities for constructed 
systems are as flexible as nanoparticles,with the difference that they 
are constituted by lipids, which have the advantage of being more biocompatible 
than metals, silica or polymers. Also, the incorporation of 
the drug is usually higher,which increases its therapeutic effect; nevertheless, 
the low retention time can imply higher doses or more doses 
over time (Muller et al., 2000; Torchilin, 2005). 
Clearly, nanomaterials have a great potential for the future of 
biomedical therapeutics, with a large number of possible formulations 
to be introduced to the pharmaceutical market. However, until now, 
only a few nanomaterials targeting infection were approved by FDA 
(Table 1). Different nanoparticles and liposomes are being developed 
each month, applied to specific bacterial species or with a broad-range 
action, having also greater therapeutic action. The future lies in how to 
overcome the limitations that the systems already developed have 
shown, such as toxicity, drug release efficiency, specificity, or the ability 
to fight the multi-resistant pathogens that have evolved on recent decades. 
In this regard, one possibility is to combine more than one antimicrobial 
agent, whether encapsulated or present in the NP material 
(Huh & Kwon, 2011). Incorporating specific antibodies into the metallic 
NP surface to increase its specificity is just one ofmany examples of how 
to obtain a promising drug (Norman et al., 2008). Another possibility is 
to use silver nanoparticles-embedded polymersomes, with ampicillin 
incorporated in the hydrophilic compartment, which had shown to 
have promising results against a resistant strain of E. coli (Geilich et al., 
2015). Even more ambitious is combining silver nanoparticles (those 
that showed the best anti-biofilmresults) (Palanisamy et al., 2014), carrying 
antimicrobial drugs for delivery (like antimicrobial peptides or 
commercially available drugs), with antibodies to improve the specificity 
for the targeting bacteria. This could be a future approach in the design 
of newNPs (Fig. 2). Themain objective, besides direct therapeutics, 
will be the use of these improved nanomaterials in a synergistic approach 
with biomedical devices, in order to overcome the bacterial infections 
that occur so frequently. 
7. Construction of novel biomedical devices 
Biomedical devices play an important role in healthcare practice, 
being essential for the treatment of diverse pathologies (Zhu et al., 
2014). Catheters, implants, prosthetic joints or sutures are nowadays 
used in several clinical treatments, but their application is associated 
with an increase in risks of infection. Nearly 45% of infection pathologies 
are device-related, involving bacterial adhesion to the device and subsequent 
proliferation and biofilmdevelopment (Romling et al., 2014; Zhu 
et al., 2014). In order to overcome these biofilminfections, novel protective 
devices need to be designed in a way that can prevent attachment 
or that have an inherent antimicrobial activity, promoting degradation, 
detachment and interference in biofilm regulation and/or development 
(Romling et al., 2014). In addition, antibiotic resistance has grown in recent 
decades, making it necessary to fight these super-resistant bacteria 
that promote device-related infections and that are so difficult to eradicate 
with the current possible treatment (de la Fuente-Núñez et al., 
2013). 
The approaches used so far in order to construct devices applied in 
therapeutics have followed different strategies, but the most well 
known and studied are: the coating of the material with molecules 
that have an antimicrobial effect (bactericidal surfaces) or the alteration 
of surface architecture in order to prevent the attachment of bacterial 
cells (anti-biofilm surfaces) (Hasan et al., 2013). 
In order to create biomedical devices that avoid bacterial infections, 
bactericidal surfaces have also been developed. Bactericidal surfaces 
are characterised by the capacity to induce cell disruption and cell 
death, either by being in contact with bacterial cells or by releasing an 
effective antimicrobial agent (Hasan et al., 2013). In this case, nanotools 
developed recently have played a major role, coating the biomedical devices 
with molecules that have shown the most promising results in 
terms of therapeutics, like nanoparticles or liposomes (Zhao et al., 
2009; Zhu et al., 2014). This type of surface has the advantage of delivering 
the drugs directly into the infection site, resulting in high local 
drug doses without exceeding the systemic drug toxicity and preventing 
possible side effects (Costa et al., 2011). 
Naturally, nanoparticles have played an important role here as well, 
being coated to thematerials by different techniques and being different 
in constitution, but alwayswith the purpose of reducing the adhesion of 
bacteria cells, and even bactericidal properties. Silver nanoparticles 
have been implanted in plastic catheters, and have shown good results 
in retarding biofilm formation (Roe et al., 2008). Also, in a different 
approach to attach the NPs to the surface, Tran and collaborators have 
incorporated Ag NPs on a hydrophobic polymer in situ, trying to improve 
the silver ion release and taking advantage of the stabilising effect 
of the polymer (Tran et al., 2015). As an alternative to metal implants, 
Travan et al. (2011) have designed a polymeric thermoset that functions 
as a fibre-reinforced composite, using bisphenol A glycidylmethacrylate 
(BisGMA) and triethyleneglycol dimethacrylate (TEGDMA), formed by 
Ag NPs stabilised in a lactose-modified chitosan. This complex design 
had an antimicrobial effect due to the presence of Ag NPs on the surface, 
resulting from the proximity to bacterial cells. Furthermore, the use of 
other nanoparticles has also been tested, like copper nanoparticles (Cu 
NPs). The nanoparticles were incorporated into a nickel layer, forming 
a film, in order to incorporate copper more efficiently on the surface 
tested (in this case, a titanium surface) (Vishwakarma et al., 2009). 
The killing effect on bacteria was due to the release of Cu ions to the environment, 
but the toxicity of these nanomaterials was questioned. Additionally, 
following previous work with MgF2 NPs, the therapeutic 
effect of these nanoparticles deposited on latex-based catheters was 
evaluated (Lellouche et al., 2009, 2012). The authors coated the surfaces 
using a sonochemical process, which was shown to be very efficient. 
However, although the therapeutic action of the NPs seemed promising, 
it needs to be more extensively tested, and the cytotoxicity to the patient 
has to be analysed (Lellouche et al., 2012). Finally, still in the possible 
uses of NPs, chitosan nanoparticles were tested as antimicrobial 
agents and simultaneously as a remineralising agent of the dentin structure. 
In this case, chitosan acts as an antimicrobial molecule but also 
stimulates remineralisation by binding to calcium ions of the dentin 
structure, through phosphate groups. At the end, the reaction will 
form a calcium phosphate layer that reconstructs the demineralised 
structures of the dentin (Carpio-Perochena et al., 2015). 
Besides nanoparticles, metals have been used on different surfaces 
in order to give them an antimicrobial effect to the material. Again, 
the most extensively studied material is silver. Researchers have tested 
the incorporation of Ag+ ions in high-density polyethylene layers that 
are used in burn dressings (Acticoat™) (Khundkar et al., 2010). In this 
particular material, the metal is present at the bottom of the layers, 
allowing a slowrelease,which results in less frequent dressing changes. 
In another study using silver nitrate (AgNO3), the authors used a photocatalytic 
activity initiatedwith radiation to forma titanium surfacewith 
different silver concentrations. The efficiency of the process was tested, 
butmore studies regarding the cytotoxicity and the antimicrobial activity 
are needed in order to apply this technique to biomedical devices 
(Seery et al., 2007). Gallium (Ga3+) was also tested as an antimicrobial 
agent in biomedical materials. This metal is chemically similar to iron 
(Fe3+), and this similarity is used to achieve an antimicrobial effect, entering 
the biological systems of the bacterial cells and replacing the iron 
ions. The fact that Ga3+ cannot be reduced like Fe3+, leading to the disruption 
of the biological systems, reinforces the potential use of this 
metal (Cochis et al., 2015). 
 
Table 1 - Examples of United States Food and Drug Administration (FDA) approved 
drugs considered as nanomaterials against infections (Bawa, 2013). IV—intravenous 
injection; SQ—subcutaneous injection; SG — subgingival injection; PGLA — 
poly(glycolide-co-di-lactide); N.A. — not applicable. 
 
 
Alternatively, for the construction of biomedical devices that have 
a bactericidal behaviour, the potential use of peptides that target different 
components of the bacteria cells or biofilm has been examined. 
Lactoferricins, peptides with antimicrobial activity, were conjugated 
with titanium binding peptides.With the attachment of these peptides, 
besides the antimicrobial activity that the surface showed, the material 
inhibited biofilm formation, but more studies have to be done in order 
to understand the mechanism of the bactericidal activity (Yoshinari 
et al., 2010). In another study, Li et al. (2015) developed a fusion peptide 
with the objective of coating biomedical devices and introducing an antimicrobial 
activity. The fusion peptide is composed of two peptides, 
where one has antimicrobial activity only at high concentrations (competence- 
stimulating peptide, CSP), but the surfaces coated have only 
appeared to present anti-biofilm formation activity, without suppressing 
bacterial growth (Li et al., 2015). 
Synthetically or naturally isolated antimicrobial peptides (AMPs) are 
themost studiedmolecules used to coat biomedical devices, due to their 
broad spectrum activity, minimal bacterial resistance, long-term stability 
and low cytotoxic profile (Costa et al., 2011; Lim et al., 2015). The 
strategies to coat a surface with AMPs have been well documented 
and tested, with a great variety of surfaces tested (like polymeric 
brushes, self-assembled monolayers, metal or even contact lenses) 
(Willcox et al., 2008). One study immobilised LL-37 (a natural human 
antimicrobial peptide) by silanisation on a titanium (Ti) surface, using 
poly(ethylene glycol) (PEG) as a spacer between the surface and the 
peptide (Gabriel et al., 2006). The authors confirmed the covalent 
bond of the AMP to the Ti surface, as well as the antimicrobial activity 
against E. coli (Gabriel et al., 2006). Using the same type of surface, 
researchers attached an AMP using silane as the chemical linker. The 
peptide tested, GL13K, had already demonstrated antimicrobial activity 
in vitro and in vivo against different bacteria strains. In this study, the 
stability over time was tested when impregnated on a Ti surface, showing 
promising results (Holmberg et al., 2013). Other researchers used a 
lactoferricin peptide (hfl1-11) testing two different methods of immobilisation 
on titanium surfaces. Both of them (physical adsorption and 
covalent immobilisation) used silane for the attachment of the peptide 
to the surface, having good results against bacterial cells and biofilm formation 
(Godoy-Gallardo et al., 2014). Regarding the silicone surfaces, 
the most used in medicine, tests have been carried out to coat them 
with antimicrobial peptides after pre-treatment with polymers (PEG), 
which served as spacers between the surface and the peptide, achieving 
good results (Mishra et al., 2013). Gao et al. (2011) also tested the use of 
polymers to attach AMPs to a quartz surface, assessing antimicrobial activity 
against bacteria and biofilms in vivo. The results were promising, 
but the mechanism through which the AMP accomplished the inhibition 
of bacteria and biofilm development was not clarified (Gao et al., 
2011, 2012). Trying to tether two different AMPs to a polydimethylsiloxane 
surface (PDMS), allyl glycidyl ether (AGE), a polymer, was used 
as a spacer, binding them covalently. In both cases the surfaces coated 
showed antibacterial and anti-biofilm activities (Hilpert et al., 2009; 
Lim et al., 2013). Moreover, different spacers were tested in order 
to conclude if there is a relationship between the molecules used. The 
results confirmed that independently of the linker chemistry. AMPs 
tethered to a cellulose surface are able to induce the death of bacteria 
only using electrostatic interactions with the biomembranes, without 
needing to enter the cell membranes (Li et al., 2014). 
Another possibility is to immobilise the peptide in self-assembled 
monolayers, which will function as a linker between the surface 
and the peptide. To this end, researchers have tested a natural AMP, 
magainin I, attached to a gold surface, concluding that the antimicrobial 
activities were maintained, even demonstrating possible anti-biofilm 
activities (Humblot et al., 2009). In fact, there is a rising number of 
peptides attached to biomedical surfaces that have shown encouraging 
results, using spacers for the attachment (G. Zhou et al., 2015; L. Zhou 
et al., 2015). More studies regarding stability, activity and biocompatibility 
are necessary before applying themin therapeutics. Among several 
other examples, AMPs have shown to be the most promising 
bactericidal molecules in the prevention of biomedical devicesassociated 
infection. In the future, new natural or synthetic peptides 
are expected to appear in the pharmaceutical market that could potentially 
be applied on the coating of these devices. 
The use of bactericidal surfaces is known to be effective, but there are 
many doubts related to specificity and the therapeutic long-term effect 
after the first contact with physiologic fluids (Campoccia et al., 2013; 
Hasan et al., 2013). Due to these reservations, the importance of 
nanotopography in resisting and preventing the cellular attachment 
was recently recognised, originating a new type of anti-biofilm surface 
(Truong et al., 2010). 
For a surface that naturally repels bacterial cells and that prevents 
biofilm formation, it is necessary to pay attention to the physicochemical 
properties, similar to those used to design liposomes for drug delivery. 
Modification of the surface can occur by functionalisation/derivatisation 
or by polymerisation (Anselme et al., 2010; Hasan et al., 2013). To 
functionalise and derivatise the surfaces, it is necessary to consider at 
least one of the chemical properties, like hydration, hydrophobicity or 
charge, adapting them to repel the bacteria that are more capable of attachment 
(Bazaka et al., 2011). A recent study has developed a method 
that uses microwave radiation to change the native oxide titanium 
film, promoting an antimicrobial effect. The mechanism by which this 
occurs is not yet well understood, but the results were promising 
(Gopal et al., 2015). Also, some studies have shown that surface roughness 
(that is associatedwith hydrophobicity) is determinant for bacterial 
infection, regarding the effectiveness of the attachment (Anselme et al., 
2010). 
Polymerisation could also be classified as a method that creates 
bactericidal surfaces, because some of the polymers tested involve the 
use of an antimicrobial agent that covalently binds the surface, but 
due to the chemical changes that occur during the process, it can also 
be considered an anti-biofilm surface (Hasan et al., 2013). As examples 
of coatings for bactericidal surfaces, in addition to the incorporation of 
antimicrobial molecules, polymers with functional groups (tertiary 
amines or N-alamines) or polymers realeasing nitric oxide or oxygen 
reactive species have also been tested (Nablo et al., 2005; Wang et al., 
2011). Focusing on polymers that promote an anti-adherent behaviour 
in the devices, Yang et al. (2011) showed the potential use of a powerful 
anchor to activate and increase the efficiency of the surface-initiated 
polymerisation, using the polymerised version of 2-hydroxyehtyl- 
methacrylate (HEMA), (PolyHEMA, PHEMA). An additional study 
showed the possible use of poly(ethylene oxide) (PEO) covalently 
bonded to the surface as a polymer that reduces the adhesion of bacteria 
cells. Even so, the study was only tested on a glass surface, needing 
more tests on other biomedical surfaces (Roosjen et al., 2003). 
Poly(sulfobetaine methacrylate) (pSBMA) and poly(carboxybetaine 
methacrylate) (pCBMA), as zwitterionic polymers, also formed polymeric 
surfaces that are highly resistant to biofilm formation and bacterial 
accumulation. The authors attributed this resistance to intrinsically 
strong hydration via electrostatic interactions and hydrogen bond interactions, 
but tests in medical devices need to be assessed (Cheng et al., 
2007). Incorporation of an enzyme (glycoside hydrolase dispersin B, 
DspB) within a layer-by-layer hydrogel, formed by a polymer (poly- 
N-acetylglucosamine, PNAG), was likewise tested and showed promising 
results in inhibiting biofilm formation (Pavlukhina et al., 2012). 
Finally, combining methacryloyloxydecyl phosphate (MDP) with PEG, 
researchers found a new treatment that inhibits the attachment of bacteria 
to hydroxyapatite (HA) surfaces (used in numerous biomedical 
devices, like prosthetic and dental implants), testing these polymers 
also in vivo with positive results (Shimotoyodome et al., 2007). Even 
with the limitations already shown, the great advantages of polymers 
are their stability and biocompatibility, which iswhy they are so attractive 
for use in biomedical devices. 
Another example of methods that prevent the formation of biofilms 
is the surface-active agents produced by microorganisms, known as 
biosurfactants. These compounds are similar to polymers, acting asmolecules 
that can disrupt membranes, leading to cell lysis and finally 
death, or as anti-adhesion molecules that delay biofilm formation 
(Banat et al., 2000, 2014). In terms of characterisation, they are produced 
mainly by microorganisms, being amphipathic, which allows 
themto accumulate at the interface between lipid phases. Lipopeptides 
(like polymixin and surfactin) and glycolipids (like rhamnolipid and 
shorolipid) are just two classes of biosurfactants that have shown 
their potential to prevent biofilm attachment (Banat et al., 2014; Díaz 
De Rienzo et al., 2015; Inès & Dhouha, 2015). In the last decade, some 
authors have tried to develop this type of surfaces, but more studies 
need to be done in order to properly assess the activity of these devices. 
One of the studies focused on the pre-inoculation of the material with 
non-pathogenic bacteria, which acted similarly to a vaccine. Even 
being a promising result, the non-pathogenic character of the bacteria 
was questioned (Trautner et al., 2002). 
In a different approach, modulating the immune system could be 
also an alternative to developing biomedical devices against infections. 
Researchers have shown that nanoscale-coating the surfaces with IL- 
12, a cytokine that promotes cell-mediated immunity, stimulates the 
natural body defense system against bacterial infections (Li et al., 
2009). The use of bacteriophages, viruses that selectively infect bacteria 
and promote lysis, has also been addressed with regard to biomedical 
surfaces, synergistically with the antibiotic ciprofloxacin. Even though 
they presented promising results against bacteria, the disadvantage 
of these systems is the bacterial resistance to the phage, which can be 
manipulated only through genetic methods (Jikia et al., 2005; Carson 
et al., 2010). Another possibility is to use polymeric matrixes that bind 
DspB, an enzyme that is able to disperse and detach mature biofilms 
fromnumerous bacteria strains. The synergistic action of DspB with antibiotics 
(cefamandole nafate, CFE) or with antimicrobial molecules 
(like triclosan, a common antiseptic) on catheters coated with them, 
make this combination a promising strategy to develop materials that 
have simultaneously antimicrobial (promoted by the antimicrobial 
molecule) and anti-biofilmactivity (due to the presence of the enzyme) 
(Donelli et al., 2007; Darouiche et al., 2009). 
As observed, numbers of different approaches and/or compounds 
can be used to develop biomedical devices that aimto control or prevent 
infectious biofilms. Certainly, promising devices in a medical context 
would be those that present potent anti-biofilm action and minimal or 
nontoxic effects on patients that depend on these devices. Studies in 
this line should also consider this parameter in order to develop new 
anti-biofilm devices. 
8. Conclusion and prospects 
Microbial biofilms are a challenge in the biomedical context, especially 
when they develop on human surfaces or implanted medical devices. 
Recent intensification of research to understand microbial 
biofilms and to develop new anti-biofilm therapies, anti-biofilm medical 
devices and diagnostics tools has provided a hope in this challenging 
clinical scenario. This has indicated that an integration of different strategies 
can be successful to combat pathogenic biofilms.Webelieve that a 
better understanding of microbial biofilms profile associated with 
optimised resources (anti-biofilm agents, biomedical devices and diagnostic 
tools) will provide in the future, a fast, inexpensive, potent and 
safe weapons to combat pathogenic biofilms. 
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